Earendil Labs Inc

Earendil Labs, based in the US, specializes in advanced AI platforms aimed at transforming protein therapeutics research and development, enhancing drug discovery processes and fostering innovation in the pharmaceutical sector. Founded in 2024 in New York, US, Earendil Labs Inc focuses on applying artificial intelligence to advance drug discovery for protein therapeutics. The company has received USD 787 mn in total funding, with their most recent funding round completed on March 25, 2026. The company was funded by a group of investors including Dimension Management, DST Global, INCE Capital, Luminous Ventures, Miracle Capital Group, Hillhouse Investment, and Sanofi Ventures.

The founder's history is currently unspecified as no prior companies are mentioned. Earendil Labs specializes in the development of advanced AI platforms specifically designed to revolutionize protein therapeutics research and development. Their core offerings focus on utilizing artificial intelligence to discover and develop novel drugs, addressing critical challenges in the pharmaceutical industry, such as the need for more effective and targeted therapies. The company's technology aims to streamline the drug discovery process, ultimately reducing time and costs associated with bringing new therapeutics to market.

Earendil Labs serves a diverse client base that includes biotechnology firms, pharmaceutical companies, and research institutions, primarily targeting markets in North America, Europe, and Asia. By harnessing AI-driven insights, their platforms facilitate the identification of promising drug candidates, providing significant value to end-users involved in drug development. Earendil Labs generates revenue through strategic partnerships and collaborations with various stakeholders in the healthcare and pharmaceutical sectors. Business transactions typically involve B2B agreements, where the company licenses its AI technology to clients for drug discovery projects.

These partnerships can include subscription-based models, allowing clients to access proprietary software tools and algorithms that enhance their research capabilities. In addition, revenue may also stem from milestone payments tied to the successful development of drug candidates that utilize their platforms. While specific pricing plans are not disclosed, the company's focus on providing high-value solutions in protein therapeutics positions it favorably within the competitive landscape of drug development. In March 2026, Earendil Labs Inc raised USD 787 mn in venture funding to develop its artificial intelligence platform, expand its biologics pipeline, and grow its research teams.

The company plans to launch new products designed to further enhance drug discovery capabilities, while targeting expansion into new markets across Europe and Asia by 2027. The recent funding will support these initiatives, allowing Earendil Labs to enhance its technology and broaden its reach within the pharmaceutical industry.